Cingulate posts narrower Q3 loss, cash jumps to $10M as it advances ADHD drug toward mid-2025 NDA

Cingulate Inc.

2024-Q3 EPS reported -$10.06

Net loss $3.2M vs $6.0M in Q3 2023; R&D expenses fell $2.5M to $1.4M.
Cash and equivalents $10M at Sep 30, 2024, up from $52K at Dec 31, 2023.
Working capital $9.8M, an increase of $19.5M from negative $9.6M at year-end 2023.
Raised ~$12.5M in Q3; cash runway extended into Q3 2025.
Commenced final FDA food-effect study for CTx-1301; data readout by end of 2024; NDA submission targeted mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.